Capricor licenses exosome platform tech from Johns Hopkins

By The Science Advisory Board staff writers

April 30, 2021 -- Biotech company Capricor Therapeutics announced it has signed an exclusive worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics in its exosome technology portfolio.

The agreement will enable Capricor to exclusively develop, manufacture, and commercialize intellectual property related to exosome technology for applications across both vaccine and therapeutic areas, with the right to sublicense. The licensed technology is based on research conducted in partnership with Stephen Gould, PhD, a Capricor executive consultant and professor of biological chemistry at Johns Hopkins.

The ease with which exomes cross cell membranes and their ability to communicate in native cellular language makes them a promising class of novel therapeutic agents, according to the company.

Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.
Reaction Biology, 4HF Biotec offer new cell-based services
Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their...
Online tool tracks COVID-19 vaccine development
A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University...
Caris brings precision medicine assays closer to market
Caris Life Sciences has submitted premarket approval applications to the U.S. Food and Drug Administration for its MI Exome CDx and MI Transcriptome CDx...
Study identifies new therapeutic targets to help patients with lung cancer
A research team at Johns Hopkins University identified new therapeutic targets that will help increase the efficacy of current immunotherapies and reduce...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter